AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 81 min read$PCRX

Pacira BioSciences to Be Acquired by Viatris in $36.50-Per-Share All-Cash Tender Offer

Pacira BioSciences (PCRX) agreed to be acquired by Viatris for $36.50 per share in an all-cash tender offer. The deal requires a majority of shares to be tendered and HSR clearance, with no shareholder vote needed. Upon completion, Pacira will become a Viatris subsidiary, and remaining shares will be cashed out at the same price, according to the companies.

Original reporting
tradingview.com
Published Oct 8, 2026, 1:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Pacira BioSciences to Be Acquired by Viatris in $36.50-Per-Share All-Cash Tender Offer — source image
Source · tradingview.com
Decision brief

The 30-second read

$PCRXBullishHigh
01

Why it matters

The cash tender offer provides immediate value to Pacira shareholders while expanding Viatris' product portfolio, though financing and integration risks remain.

02

Market read

The deal is a material M&A event in the healthcare sector, likely moving both stocks and influencing sector sentiment.

03

What to watch

Regulatory HSR clearance timing and potential antitrust hurdles could delay or alter deal terms.

Relevance 9/10Novelty 9/10Timing: today

Background

Pacira BioSciences (PCRX) and Viatris (VTRS) disclosed a definitive merger agreement, with Pacira to become a wholly owned subsidiary of Viatris.

Company-level read

Ticker impact

$PCRXBullishHigh confidence
Context

Pacira BioSciences announced an all‑cash $36.50 per share tender offer by Viatris, indicating a definitive acquisition agreement.

Expected impact

upward pressure on PCRX as cash premium is priced in; potential dilution pressure on VTRS.

Evidence & confidence

The cash offer at $36.50 per share represents a premium to recent trading levels, driving likely price appreciation for PCRX.

$VTRSNeutralHigh confidence
Context

Viatris agreed to acquire Pacira BioSciences in an all‑cash tender offer of $36.50 per share.

Expected impact

slight downside pressure on VTRS as market prices acquisition cost and potential dilution.

Evidence & confidence

The deal size and cash outlay could weigh on Viatris' balance sheet, tempering its share price.

Market effects

Sector

Further consolidation in the pharmaceutical/biotech sector, potentially prompting additional M&A activity.

Regional

Impacts US healthcare sector valuations and investor sentiment.

Global

Highlights cross‑border M&A trends and may influence global pharma deal pipelines.

Counterpoint

What could challenge this read

The acquisition could be overvalued; integration risks may erode expected synergies.

Key entities

  • company
    Pacira BioSciences

    Target of the acquisition, ticker PCRX.

  • company
    Viatris

    Acquirer, ticker VTRS.

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 8
$PCRXHighAI 9/10

Why is Pacira BioSciences stock surging today?

Pacira BioSciences (PCRX) stock surged 44.2% after Viatris (VTRS) agreed to acquire it for $36.50 per share, or $1.65 billion. The deal, expected to close by 2026, adds two patented products to Viatris' portfolio. Truist Securities raised its price target to $31. The acquisition is seen as strategically important by Viatris' CEO.

investing.com2 min
OCT 8
$VTRSHighAI 9/10

Viatris to acquire Pacira BioSciences for $1.65 billion

Viatris (VTRS) will acquire Pacira BioSciences (PCRX) for $1.65B, or $36.50 per share. The deal adds two patented drugs to Viatris' portfolio. Pacira reported $746M revenue and $177M adjusted EBITDA in the last 12 months. The transaction is expected to close by year-end 2026 and is immediately accretive to Viatris' financials, according to the companies.

investing.com2 min
OCT 8
$VTRSHighAI 9/10

A $1.65 billion deal would put two non-opioid pain medicines under Viatris.

Viatris (VTRS) agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion, or $36.50 per share in cash. Pacira reported $746 million in revenue and $177 million in adjusted EBITDA for the year ended June 30, 2026. The deal is expected to close by the end of 2026, subject to regulatory approvals and tender of a majority of Pacira's shares. Pacira's shares will no longer trade on Nasdaq upon completion. Viatris aims to expand Pacira's products, EXPAREL and ZILRETTA, into international markets.

stocktitan.net3 min
OCT 8
$VTRSHighAI 9/10

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Viatris Inc. (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion, or $36.50 per share. Pacira's products, EXPAREL and ZILRETTA, generated $746 million in revenue and $177 million in adjusted EBITDA in the last 12 months. The deal is expected to close by the end of 2026 and be immediately accretive to Viatris' financial guidance. Viatris plans to leverage its global infrastructure to expand the reach of Pacira's products.

prnewswire.com3 min